EndoTODAY | EndoATLAS | Outpatient Clinic

Parasite | Esophagus | Stomach | Cancer | ESD

Home | Guide | Author | Search | Blog | Links


[¼­¿ï¾Æ»êº´¿ø ¿°Áõ¼º ÀåÁúȯ ¼¾ÅÍ Á¦6ȸ ½ÉÆ÷Áö¾ö (2017)]

ÀϽÃ: 2017³â 7¿ù 23ÀÏ ¼­¿ï¾Æ»êº´¿ø

¸Å¿ì ¸ÚÁø ½ÉÆ÷Áö¾öÀ̾ú½À´Ï´Ù. ¾ç¼®±Õ ±³¼ö´Ô¿¡ ÀÇÇÏ¸é »çÀüµî·ÏÀÌ 400¸í ÀÌ»óÀ̶ó°í ÇÕ´Ï´Ù. Àú¸¦ Æ÷ÇÔÇÏ¿© ÇöÀå µî·ÏÀÚµµ ¸Å¿ì ¸¹¾Ò½À´Ï´Ù.

Âü¼®ÇϽŠ¾î¶² ¼±»ý´Ô²²¼­ ÀÌ·± comment¸¦ Áּ̽À´Ï´Ù. "±¹³» Àǻ縦 À§ÇÑ ½ÉÆ÷Áö¾öÀº ¿ª½Ã Çѱ۷ΠÇØ¾ß È¿°úÀûÀ̶ó´Â °ÍÀ» ´Ù½Ã±Ý ±ú´Þ¾Ò½À´Ï´Ù." ÀüÀûÀ¸·Î µ¿ÀÇÇÕ´Ï´Ù. ¿ì¸®³ª¶ó Àǻ簡 ¿ì¸®³ª¶ó ȯÀÚ¿¡ ´ëÇÏ¿© °øºÎÇÏ´Â ½ÉÆ÷Áö¾öÀ» ¿µ¾î·Î ÇÑ´Ù´Â °ÍÀº ¸»µµ µÇÁö ¾Ê´Â ÀÏÀÔ´Ï´Ù. ±¹³» ÇÐȸ´Â Áö¿øÇÏÁö ¾Ê°í (Çã¿ï»ÓÀÎ) ±¹Á¦ ÇÐȸ¸¸ Áö¿øÇÏ´Â Á¤ºÎ Á¤Ã¥Àº ´çÀå ÁߴܵǾî¾ß ÇÕ´Ï´Ù. »ç´ëÁÖÀǵµ ÀÌ·± »ç´ëÁÖÀÇ°¡ ¾ø½À´Ï´Ù.


1. Back to basics: Correct diagnosis and proper treatment of IBD

[±è¿øÈ£ ±³¼ö´Ô comment] °ú°Å¿¡´Â ¿°Áõ¼º ÀåÁúȯÀÇ under diagnosis¿Í under treatment°¡ ¹®Á¦¿´´Âµ¥, ÀÌÁ¦´Â over diagnosis¿Í over treatment°¡ °ÆÁ¤ÀÎ ½Ã´ë°¡ µÇ¾ú½À´Ï´Ù. ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ Á߸³ÀûÀÎ ½Ã°¢À» °¡Áú ¶§ ÁøÁ¤ÇÑ ¹ßÀüÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.


1) Diagnosis, activity evaluation, and classification (°æºÏÀÇ´ë ±èÀº¼ö)

8°³ÀÇ red flagÀÌ Á¦¾ÈµÇ¾ú½À´Ï´Ù. (Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative - J Crohns Colitis 2015)

  1. Non-healing or complex perianal fistula or perianal lesions (apart from hemorrhoids)
  2. First-degree relative with continued inflammatory bowel disease
  3. Weight loss (5% body weight in the last 3 months)
  4. Chronic abdominal pain (>3 months)
  5. Nonturnal diarrhea
  6. Mild fever in the last 3 months
  7. No abdominal pain 30-45 min after meals, predominantly after vegetables
  8. No rectal urgency

¾ÏÀº sensitivity°¡ Áß¿äÇϹǷΠscreening °³³äÀ¸·Î Á¢±ÙÇØ¾ß ÇÕ´Ï´Ù. ¿°Áõ¼º ÀåÁúȯÀº specificity°¡ Áß¿äÇϹǷΠ¸ðÈ£ÇÑ °æ¿ì´Â wait and see Àü·«, Áï ½Ã°£ °£°ÝÀ» µÎ°í ´Ù½Ã Æò°¡ÇØ¾ß ÇÕ´Ï´Ù.

°úÀ× Áø´ÜÀº Àå±â°£ÀÇ ºÒÇÊ¿äÇÑ Ä¡·á·Î ¿¬°áµÉ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

Perianal disease´Â ¿ì¸®³ª¶ó ȯÀÚ¿¡¼­ Á» ´õ ÈçÇÕ´Ï´Ù.


2) Endoscopic and radiologic evaluation (¼­¿ïÀÇ´ë À±Çõ)

Capsule endoscopy: Æó¼â Áõ»óÀ̳ª ¼ÒÀåÀýÁ¦·ÂÀÌ ¾ø´Â suspected CD¿¡¼­ÀÇ retention rate´Â obscure GI bleeding¿¡¼­¿Í ºñ½ÁÇÒ Á¤µµ·Î ³·Áö¸¸, established CD¿¡¼­´Â capsule retention rate°¡ ÇöÀúÈ÷ Áõ°¡ÇϹǷΠ´Ù¸¥ imagingÀ» ¸ÕÀú ÇØ¾ß ÇÕ´Ï´Ù. (1.6% vs 13%)

MRI´Â ´ë°­ CT¿Í ºñ½ÁÇѵ¥, fistula Æò°¡¸¦ À§Çؼ­´Â MRI°¡ ´õ À¯¿ëÇÕ´Ï´Ù. »ç½Ç MRI¸¦ ÂïÀ¸¸é »çÁøÀÌ 1,000Àå ³Ñ°Ô ³ª¿À´Â °æ¿ìµµ À־ ³»°ú ÀÇ»ç»Ó¸¸ ¾Æ´Ï¶ó ¿µ»óÀÇÇаú Àǻ絵 ±«·Î¿öÇϱ⵵ ÇÕ´Ï´Ù. ºÐ´ç ¼­¿ï´ëº´¿ø¿¡¼­´Â Gadolinium Åõ¿© 1ºÐ ÈÄ coronal image, 3ºÐ ÈÄ trasnsectional image¸¦ ¾ò°í Àִµ¥, ³»°ú ÀÇ»çµéÀº ÀÌ¿Í °°Àº T1-weighted image¸¦ Àß º¸´Â °ÍÀÌ ÁÁ½À´Ï´Ù. Fistula Æò°¡¸¦ À§Çؼ­´Â T2-weighted image°¡ À¯¿ëÇÕ´Ï´Ù.

[ÀÌÁØÇà Áú¹®]

(1) Mucosal healingÀÌ ¿¹ÈÄÀÎÀÚÀÌÁö¸¸, over-treatment·Î ¿¬°áµÇ±â ½±´Ù°í »ý°¢ÇÕ´Ï´Ù. ÀÓ»ó¿¡¼­ ¾î¶»°Ô »ç¿ëµÇ´ÂÁö¿ä? (2) ¼Ò¾Æ Å©·ÐÀÇ Áø´Ü¿¡¼­ ´Ù¸¥ Á¡Àº ¾ø½À´Ï±î?

[À±Çõ ±³¼ö´Ô ´äº¯]

(1) Mucosal healingÀ» º¸±â À§ÇÑ Ãß°¡ °Ë»ç¸¦ µû·Î ½ÃÇàÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. (2) ¼Ò¾Æ¿¡¼­´Â MRI¸¦ ´õ ÀÚÁÖ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù.

[¼ÛÀμº ±³¼ö´Ô comment & Áú¹®]

Endoscopic score¸¦ ¾²½Ã´ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ¿©·¯ parameterµéÀÌ ÇÔ²² ¿òÁ÷ÀÌÁö ¾Ê°í, ÁÖ°üÀûÀ̱⠶§¹®¿¡ Àú´Â »ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.

[À±Çõ ±³¼ö´Ô ´äº¯]

Àú´Â »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù¸¸, ÀÓ»ó¿¡¼­ À¯¿ë¼ºÀº ¾ÆÁ÷ ºÒ¸íÈ®ÇÑ ¸éÀÌ ÀÖ½À´Ï´Ù.


3) The cutting edge strategy of IBD management (¿ï»êÀÇ´ë ¿¹º´´ö)

IBD´Â heterogeneous diseaseÀ̹ǷΠÁø´ÜµÇ¸é ÀÏÂï ¿¹Èĸ¦ ¿¹ÃøÇØ¾ß ÇÕ´Ï´Ù. ¿¹ÈÄ°¡ ¾È ÁÁÀ» °ÍÀ¸·Î »ý°¢µÇ´Â °æ¿ì´Â potent drugÀ» ÀÏÂï ½á ÁÙ ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.

Control of symptom alone is not enough. → Mucosal healing°ú deep remissionÀ» ¸ñÇ¥·Î ÇÏ°í ÀÖ½À´Ï´Ù. Control of inflammationÀÌ ÃÖ±ÙÀÇ targetÀÔ´Ï´Ù.

°ú°Å¿¡´Â Åõ¾à ÈÄ ±â´Ù¸®´Â °ÍÀÌ º¸ÅëÀÌÁö¸¸ ÃÖ±Ù¿¡´Â tight monitoring and tight control Àü·«ÀÌ ±Ç°íµÇ°í ÀÖ½À´Ï´Ù.

[ÀÌÁØÇà È¥À㸻]

¿¹º´´ö ±³¼ö´Ô °­ÀÇ¿¡ ´ëÇؼ­´Â ûÁßÀÇ Áú¹®ÀÌ ¸Å¿ì ¸¹À» °ÍÀ¸·Î »ý°¢µÇ¾ú´Âµ¥ ÁøÇà °ü°è·Î ÁúÀÇ ÀÀ´ä ½Ã°£ÀÌ ¾ø¾ú½À´Ï´Ù. ¸Å¿ì ¾Æ½¬¿ü½À´Ï´Ù. ¿¹º´´ö ±³¼ö´Ô °­ÀÇ¿Í °°Àº clinical À̽´¿¡ ´ëÇؼ­´Â Àû¾îµµ 30ºÐ Á¤µµÀÇ ÁúÀÇ ÀÀ´ä ½Ã°£ÀÌ ¹èÁ¤µÇ¾î¾ß ÇÒ °Í °°½À´Ï´Ù. 1½Ã°£ÀÌ¸é ´õ ÁÁ±¸¿ä. °­ÀÇ Àý¹Ý, Åä·Ð Àý¹Ý styleÀÇ ½ÉÆ÷Áö¾öÀ» ±â´ëÇØ º¾´Ï´Ù.


2. From bench to bedside: Evolving therapies for IBD

1) Prediction of response to anti-TNF therapy: Where are we now ? (ÃæºÏÀÇ´ë À±¼ø¸¸)

[±èÈ¿Á¾ ÁÂÀå´Ô Áú¹®]

Poor outcomeÀÌ ¿¹ÃøµÇ´Â ȯÀÚ¿¡ ´ëÇÏ¿© ¹Ì¸® ¹º°¡¸¦ ÇØ ÁÙ °ÍÀº ¾ø½À´Ï±î?

[À±¼ø¸¸ ±³¼ö´Ô ´äº¯]

Genetic evalutionÀº ¾ÆÁ÷ Çö½ÇÀûÀÌÁö ¾Ê½À´Ï´Ù. ÀÓ»ó ÁöÇ¥´Â ½±°Ô ±¸ÇÒ ¼ö ÀÖÀ¸³ª outcome ¿¹Ãø·ÂÀº heterogeneousÇÕ´Ï´Ù. ¿Ü±¹¿¡¼­´Â ±Ë¾ç¼º ´ëÀå¿°ÀÌ ½ÉÇÏ¸é ¿ë·®À» ³ôÀ̰ųª Á» ´õ ÀÚÁÖ Åõ¿©Çϱ⵵ ÇÕ´Ï´Ù¸¸ ±¹³» Çö½Ç¿¡¼­´Â ÀûÇÕÇÏÁö ¾Ê½À´Ï´Ù. °á±¹ therapeutic drug monitoring (trough level ÃøÁ¤)ÀÌ »¡¸® ½ÃÇàµÇ¾î¾ß ÇÒ °Í °°½À´Ï´Ù.


2) Fecal microbial transplantation: Does it work for IBD? (°í½ÅÀÇ´ë ¹®¿ø)

FMT (¼ÒÀ§ ¶ËÀ̽Ä)Àº ¿ì¸®³ª¶ó¿¡¼­´Â 2016³â 6¿ù 'Àç¹ß¼º ¶Ç´Â ±âÁ¸ Ç×»ýÁ¦ Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â Clostridium difficile °¨¿° ȯÀÚ'¿¡¼­ ½ÅÀÇ·á±â¼ú·Î µî·ÏµÇ¾ú½À´Ï´Ù.

IBD ȯÀÚ¿¡¼­ FMT protocolÀº ´Ù¾çÇÏÁö¸¸ ÇöÀç°¡ÁöÀÇ °á·ÐÀº (1) ¸¹ÀÌ ³Ö¾î¾ß ÇÏ°í (2) ÇϺηΠ³Ö¾î¾ß ÇÕ´Ï´Ù.

* Âü°í: EndoTODAY FMT (fecal microbiota transplatation)


3. Top 10 questions about issues encountered during management of IBD patients

1) Mycobacterial diseases (¿ï»êÀÇ´ë ½Éż±) - ÁÖÀÎÀåÀÇ ¼±ÅÃ. ¿À´ÃÀÇ ÃÖ°í °­ÀÇ


2) Rheumatologic disorders (¿ï»êÀÇ´ë ±è¿ë±æ)

Q: Anti-TNF Åõ¿© ½Ã ¹ßÇàÇÏ´Â lupus¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Â ÀÓ»ó»óÀº?

A: Drug-induced lupus¿Í anti-TNF induced lupus (ATIL)°¡ ÀÖ½À´Ï´Ù. ATIL°¡ º¸´Ù ½ÉÇÑ ÇüÅ·μ­, full blown lupus·Î ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ¾àÀ» ²÷´Â °Í¸¸À¸·Î´Â ºÎÁ·ÇÏ¿© full blown lupusó·³ Ä¡·áÇÒ ÇÊ¿ä°¡ ÀÖ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ÇØ¾ß Çϱ⵵ ÇÕ´Ï´Ù.

Q: IBD ÀÚüÀÇ extra-intestinal manifestation ȤÀº ¾àÁ¦ ¶§¹®ÀÌÁö, ¾Æ´Ï¸é RA, AS °¡Àº Áúȯ ¶§¹®ÀÎÁö ±¸ºÐÀÌ ¾î·Á¿ï ¶§ RF, CCP, HLA-B27°ú °°Àº °Ë»çµéÀÌ µµ¿òÀÌ µÉ±î¿ä?

A: Anti-CCP´Â rheumatoid arthritis¿¡ ¸Å¿ì specificÇÏ¿© µµ¿òÀÌ µË´Ï´Ù. ±×·¯³ª ³ª¸ÓÁö´Â À§¾ç¼ºÀÌ ¸¹¾Æ¼­ ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù.


3) Infectious diseases other than mycobacterial diseases ¼­¿ï¾Æ»êº´¿ø Á¤¿ëÇÊ

PDF 3.4M


4. Mysteries and dilemmas in IBD: AMC case-based review

1) Young women with IBD: Pre-conception, during pregnancies, and newborn care (¿ï»êÀÇ´ë Ȳ¼º¿í)

±×·¯³ª FDA category¿Í °°ÀÌ ´Ü¼øÇÑ ±âÁØÀ» Àû¿ëÇÏÁö ¸»°í ÀÓ»ó »óȲÀ» Àß º¸°í ÇÊ¿äÇϸé ÀûÀýÈ÷ »ç¿ëÇ϶ó°í ±Ç°íµÇ°í ÀÖ½À´Ï´Ù.


2) Skin problems in patients: What gastroenterologists should know (¿ï»êÀÇ´ë ¿øÁ¾Çö)


3) Diagnosis and management of colorectal dysplasia in IBD patients ¿ï»êÀÇ´ë ¾çµ¿ÈÆ

Cancer »ó´ÜÀÇ Á¡¸· Ç¥¸éÀº ¾Ï Á¶Á÷ÀÌ ¾Æ´Ï¾ú±â ¶§¹®¿¡ ³»½Ã°æ¿¡¼­ ¹ß°ßÀÌ ´õ ¾î·Á¿ü´ø °Í °°½À´Ï´Ù.

¾Æ»êº´¿ø Áõ·Êµé¿¡ ´ëÇÑ ºÐ¼®ÀÔ´Ï´Ù.


[References]

1) EndoTODAY ¼­¿ï¾Æ»êº´¿ø ¿°Áõ¼ºÀåÁúȯ¼¾ÅÍ Á¦5ȸ ½ÉÆ÷Áö¾ö (2016)

2016

2) ¼­¿ï¾Æ»êº´¿ø ¿°Áõ¼ºÀåÁúȯ¼¾ÅÍ È¨ÆäÀÌÁö Å©·Ðº´ ȯÀÚ¼³¸íÀÚ·á (µ¿¿µ»ó)

3) ¼­¿ï¾Æ»êº´¿ø ¿°Áõ¼ºÀåÁúȯ¼¾ÅÍ È¨ÆäÀÌÁö ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ¼³¸íÀÚ·á (µ¿¿µ»ó)



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.